KRYS
Krystal Biotech·NASDAQ
--
--(--)
--
--(--)
4.38 / 10
Netural
Analyst consensus is bullish: both active analysts rate KRYS as Strong Buy, and historical weighted rating is 1.16. Fund-flow data confirm a positive bias, with overall, block, and extra-large inflows trending upward (ratios ~0.50-0.52), while medium and large flows show mild pullbacks. Sentiment score of 7.59/10 underscores robust capital interest. Together, analyst conviction and fund inflows support the technical upswing, but the neutral overall rating reminds investors to monitor valuation and profit efficiency closely.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-22
InstitutionB of A Securities
Times predicted3
Historical Win Rate33.3%
Is money flowing into or out of KRYS?
- KRYS holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 4.38/10 (Netural).
